Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2309 in CD70+ relapsed/refractory hematologic malignancies
NCT07173595Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS2309 in hematologic malignancy, sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 28 days and Recommended Phase II Dose at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
QLS2309
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07173595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173595.